Jasper Therapeutics Says Health Canada Cleared Phase 1b/2a Briquilimab Asthma Study
Jasper Therapeutics (JSPR) said Tuesday that Health Canada has cleared its clinical trial application for a phase 1b/2a asthma challenge study assessing briquilimab, an antibody therapy for mast cell-driven diseases.
The phase 1b/2a asthma study is expected to enroll 30 patients across 10 sites in Canada and the European Union, aiming to validate briquilimab's efficacy, with dosing beginning in Q4 and results expected in H2 2025, the company said.
The biotechnology company also said its c-Kit Mouse model has received a registered trademark from the US Patent and Trademark Office for its ability to test c-Kit or CD117 inhibitors in various diseases.
Price: 18.92, Change: -0.38, Percent Change: -1.97
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.